Waymond D Bray

Array ( [id] => 17314403 [patent_doc_number] => 20210403451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => PYRIMIDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/288707 [patent_app_country] => US [patent_app_date] => 2019-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15425 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17272889 [patent_doc_number] => 20210379087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS [patent_app_type] => utility [patent_app_number] => 17/288508 [patent_app_country] => US [patent_app_date] => 2019-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24342 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292102 [patent_doc_number] => 20210387941 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => Diphenyl-like Compound, Intermediate Thereof, Preparation Method Therefor, Pharmaceutical Composition Thereof And Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/288946 [patent_app_country] => US [patent_app_date] => 2019-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14294 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292107 [patent_doc_number] => 20210387946 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING A SUBSTITUTED INDANE AND METHODS FOR THE PREPARATION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/286581 [patent_app_country] => US [patent_app_date] => 2019-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17286581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17241926 [patent_doc_number] => 20210361669 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/288164 [patent_app_country] => US [patent_app_date] => 2019-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52574 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17272874 [patent_doc_number] => 20210379072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => NOVEL USES [patent_app_type] => utility [patent_app_number] => 17/287478 [patent_app_country] => US [patent_app_date] => 2019-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11662 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17274381 [patent_doc_number] => 20210380579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => PROTEOLYSIS TARGETING CHIMERA (PROTACS) AS DEGRADERS OF SMARCA2 AND /OR SMARCA4 [patent_app_type] => utility [patent_app_number] => 17/285491 [patent_app_country] => US [patent_app_date] => 2019-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18018916 [patent_doc_number] => 20220370415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS [patent_app_type] => utility [patent_app_number] => 17/284200 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26768 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -277 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17284200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17272844 [patent_doc_number] => 20210379042 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => METHODS FOR MONITORING TUMOR LYSIS SYNDROME [patent_app_type] => utility [patent_app_number] => 17/284409 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14445 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -95 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17284409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17274374 [patent_doc_number] => 20210380572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/282821 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26484 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17185151 [patent_doc_number] => 20210332036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/281078 [patent_app_country] => US [patent_app_date] => 2019-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11285 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292124 [patent_doc_number] => 20210387963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/282789 [patent_app_country] => US [patent_app_date] => 2019-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19668 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299383 [patent_doc_number] => 20210395222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => Fused Bicyclic Heterocycles as Therapeutic Agents [patent_app_type] => utility [patent_app_number] => 17/282917 [patent_app_country] => US [patent_app_date] => 2019-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41765 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 539 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17334531 [patent_doc_number] => 20220000862 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => COMBINATION THERAPY FOR THE TREATMENT OF UVEAL MELANOMA [patent_app_type] => utility [patent_app_number] => 17/281453 [patent_app_country] => US [patent_app_date] => 2019-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9253 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398093 [patent_doc_number] => 20220040183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => USE OF INHIBITORS OF STRESS GRANULE FORMATION FOR TARGETING THE REGULATION OF IMMUNE RESPONSES [patent_app_type] => utility [patent_app_number] => 17/281408 [patent_app_country] => US [patent_app_date] => 2019-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11657 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281408 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314428 [patent_doc_number] => 20210403476 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => ION CHANNEL MODULATORS [patent_app_type] => utility [patent_app_number] => 17/280485 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36373 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17280485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398068 [patent_doc_number] => 20220040158 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => AZD0328 DOSAGE REGIME FOR TREATING COGNITIVE IMPAIRMENT [patent_app_type] => utility [patent_app_number] => 17/278916 [patent_app_country] => US [patent_app_date] => 2019-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3538 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278916 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17213039 [patent_doc_number] => 20210346375 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2, AS WELL AS PRODUCTS RESULTING FROM ACID ADDITION [patent_app_type] => utility [patent_app_number] => 17/280637 [patent_app_country] => US [patent_app_date] => 2019-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21254 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17280637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685770 [patent_doc_number] => 20220193062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => COMBINATION OF ENZASTAURIN AND INHIBITORS OF BTK AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/196820 [patent_app_country] => US [patent_app_date] => 2019-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17196820 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036586 [patent_doc_number] => 20210253544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => INHIBITORY MATERIAL AGAINST HUMAN BODY-DERIVED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE-DEPENDENT STEROID DEHYDROGENASE-LIKE, AND ANTICANCER AGENT COMPRISING SAME AS EFFECTIVE INGREDIENT OR PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR TREATMENT OF HYPERLIPIDEMIA [patent_app_type] => utility [patent_app_number] => 17/271354 [patent_app_country] => US [patent_app_date] => 2019-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271354 [rel_patent_id] =>[rel_patent_doc_number] =>)